Michael A. Postow, MD

Michael A. Postow, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.

In many cases, these treatments are life-saving medications, Postow says. However, it is important to recognize when a patient is experiencing side effects from the treatment so that it can be modified in order to best support the patient.

Videos

Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.

Managing Immunotherapy Toxicities in Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

COMBI-AD and BRIM8 Studies in Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the results of the COMBI-AD study and the CheckMate-238 study will impact the care of patients with melanoma.

How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses targets beyond PD-1 in melanoma.

Michael A. Postow, MD | Authors

Articles

Managing Immunotherapy Toxicities in Melanoma

COMBI-AD and BRIM8 Studies in Melanoma

How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

Targeting Beyond PD-1 in Melanoma